• Aliases: AF802; CH5424802; RG7853; RO5424802
    • A tyrosine kinase receptor inhibitor that inhibits ALK and RET resulting in decreased tumor cell viability. Alectinib is more potent than crizotinib against ALK and can inhibit most of the clinically observed acquired ALK resistance mutations to crizotinib. FDA approved for metastatic NSCLC with ALK-positive mutation or who have progressed on, or are intolerant to, crizotinib.
    • Recommended dose: 600 mg twice daily with food
    • Half-life: 33 hours (37% bioavailability under fed condition)
    • Common side effects: Edema, bradycardia, fatigue, headache, rash, hyperglycemia, hypophosphatemia, transaminitis, hyperbilirubinemia, muscle pain, eased CPK, increased SCr, constipation
    Other topics in Targeted and Immunotherapy Agents